BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 38658533)

  • 1. Ganoderic acid D attenuates gemcitabine resistance of triple-negative breast cancer cells by inhibiting glycolysis via HIF-1α destabilization.
    Luo B; Song L; Chen L; Cai Y; Zhang M; Wang S
    Phytomedicine; 2024 Jul; 129():155675. PubMed ID: 38678954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia.
    Metallo CM; Gameiro PA; Bell EL; Mattaini KR; Yang J; Hiller K; Jewell CM; Johnson ZR; Irvine DJ; Guarente L; Kelleher JK; Vander Heiden MG; Iliopoulos O; Stephanopoulos G
    Nature; 2011 Nov; 481(7381):380-4. PubMed ID: 22101433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism.
    Grassian AR; Parker SJ; Davidson SM; Divakaruni AS; Green CR; Zhang X; Slocum KL; Pu M; Lin F; Vickers C; Joud-Caldwell C; Chung F; Yin H; Handly ED; Straub C; Growney JD; Vander Heiden MG; Murphy AN; Pagliarini R; Metallo CM
    Cancer Res; 2014 Jun; 74(12):3317-31. PubMed ID: 24755473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomal formulation of HIF-1α inhibitor echinomycin eliminates established metastases of triple-negative breast cancer.
    Bailey CM; Liu Y; Peng G; Zhang H; He M; Sun D; Zheng P; Liu Y; Wang Y
    Nanomedicine; 2020 Oct; 29():102278. PubMed ID: 32738299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reductive glutamine metabolism is a function of the α-ketoglutarate to citrate ratio in cells.
    Fendt SM; Bell EL; Keibler MA; Olenchock BA; Mayers JR; Wasylenko TM; Vokes NI; Guarente L; Vander Heiden MG; Stephanopoulos G
    Nat Commun; 2013; 4():2236. PubMed ID: 23900562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MCT2 mediates concentration-dependent inhibition of glutamine metabolism by MOG.
    Fets L; Driscoll PC; Grimm F; Jain A; Nunes PM; Gounis M; Doglioni G; Papageorgiou G; Ragan TJ; Campos S; Silva Dos Santos M; MacRae JI; O'Reilly N; Wright AJ; Benes CH; Courtney KD; House D; Anastasiou D
    Nat Chem Biol; 2018 Nov; 14(11):1032-1042. PubMed ID: 30297875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia-mediated activation of hypoxia-inducible factor-1α in triple-negative breast cancer: A review.
    Liu L; Bai J; Hu L; Jiang D
    Medicine (Baltimore); 2023 Oct; 102(43):e35493. PubMed ID: 37904441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting hypoxia-inducible factor-1alpha: A new strategy for triple-negative breast cancer therapy.
    Liu Q; Guan C; Liu C; Li H; Wu J; Sun C
    Biomed Pharmacother; 2022 Dec; 156():113861. PubMed ID: 36228375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wild-type IDH2 is a therapeutic target for triple-negative breast cancer.
    Li JJ; Yu T; Zeng P; Tian J; Liu P; Qiao S; Wen S; Hu Y; Liu Q; Lu W; Zhang H; Huang P
    Nat Commun; 2024 Apr; 15(1):3445. PubMed ID: 38658533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability.
    Wise DR; Ward PS; Shay JE; Cross JR; Gruber JJ; Sachdeva UM; Platt JM; DeMatteo RG; Simon MC; Thompson CB
    Proc Natl Acad Sci U S A; 2011 Dec; 108(49):19611-6. PubMed ID: 22106302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reductive TCA cycle catalyzed by wild-type IDH2 promotes acute myeloid leukemia and is a metabolic vulnerability for potential targeted therapy.
    Zeng P; Lu W; Tian J; Qiao S; Li J; Glorieux C; Wen S; Zhang H; Li Y; Huang P
    J Hematol Oncol; 2022 Mar; 15(1):30. PubMed ID: 35313945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The heterocyclic compound Tempol inhibits the growth of cancer cells by interfering with glutamine metabolism.
    Ye S; Xu P; Huang M; Chen X; Zeng S; Wang Q; Chen J; Li K; Gao W; Liu R; Liu J; Shao Y; Zhang H; Xu Y; Zhang Q; Zhong Z; Wei Z; Wang J; Hao B; Huang W; Liu Q
    Cell Death Dis; 2020 May; 11(5):312. PubMed ID: 32366855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IDH2 reprograms mitochondrial dynamics in cancer through a HIF-1α
    Wang Y; Agarwal E; Bertolini I; Ghosh JC; Seo JH; Altieri DC
    FASEB J; 2019 Dec; 33(12):13398-13411. PubMed ID: 31530011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockdown of both mitochondrial isocitrate dehydrogenase enzymes in pancreatic beta cells inhibits insulin secretion.
    MacDonald MJ; Brown LJ; Longacre MJ; Stoker SW; Kendrick MA; Hasan NM
    Biochim Biophys Acta; 2013 Nov; 1830(11):5104-11. PubMed ID: 23876293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic reprogramming and cancer progression.
    Faubert B; Solmonson A; DeBerardinis RJ
    Science; 2020 Apr; 368(6487):. PubMed ID: 32273439
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.